Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · brain-umap@2

SRR1339530

GTEX

af03c382-545e-55da-acb1-cfba8333448c

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
—
subtype
—
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.436
  • MYOGENESIS+0.371
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.307
  • UV_RESPONSE_DN+0.283
  • SPERMATOGENESIS+0.241
  • APICAL_SURFACE+0.217
  • BILE_ACID_METABOLISM+0.215
  • ESTROGEN_RESPONSE_LATE+0.178
  • ESTROGEN_RESPONSE_EARLY+0.176
  • COAGULATION+0.173

Top 10 suppressed

  • MYC_TARGETS_V1-0.656
  • DNA_REPAIR-0.580
  • MYC_TARGETS_V2-0.549
  • UNFOLDED_PROTEIN_RESPONSE-0.544
  • E2F_TARGETS-0.480
  • MTORC1_SIGNALING-0.459
  • G2M_CHECKPOINT-0.430
  • PROTEIN_SECRETION-0.430
  • OXIDATIVE_PHOSPHORYLATION-0.403
  • PI3K_AKT_MTOR_SIGNALING-0.373

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1472079
brain-umap@2
GTEX—0.960
2SRR1334741
brain-umap@2
GTEX—0.952
3SRR1486863
brain-umap@2
GTEX—0.951
4SRR1406976
brain-umap@2
GTEX—0.947
5SRR1343281
brain-umap@2
GTEX—0.946
6SRR1355613
brain-umap@2
GTEX—0.944
7SRR1330061
brain-umap@2
GTEX—0.942
8SRR1375635
brain-umap@2
GTEX—0.942
9SRR598276
brain-umap@2
GTEX—0.941
10SRR1329761
brain-umap@2
GTEX—0.940

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.436Remibrutinib— uncovered
MYOGENESIS0.371Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.307Inavolisib— uncovered
UV_RESPONSE_DN0.283Inavolisib— uncovered
SPERMATOGENESIS0.241Inavolisib— uncovered
APICAL_SURFACE0.217Temsirolimus— uncovered
BILE_ACID_METABOLISM0.215Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.178Idelalisib— uncovered
ESTROGEN_RESPONSE_EARLY0.176Inavolisib— uncovered
COAGULATION0.173Binimetinib— uncovered
KRAS_SIGNALING_UP0.156Inavolisib— uncovered
PANCREAS_BETA_CELLS0.154Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.136Inavolisib— uncovered
ANGIOGENESIS0.132Remibrutinib— uncovered
INFLAMMATORY_RESPONSE0.123Idelalisib— uncovered
INTERFERON_ALPHA_RESPONSE0.110Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.062Idelalisib— uncovered
APICAL_JUNCTION0.059Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.021Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.015Inavolisib— uncovered